硫酸镁联合硝苯地平及拉贝洛尔治疗子痫前期高血压的价值及有效性评价

Value and Effectiveness Evaluation of Magnesium sulfate Combined with Nifedipine and Labelolol in the Treatment of Preeclampsia Hypertension

目的评估硫酸镁联合硝苯地平、拉贝洛尔应用在子痫前期高血压患者中的价值及有效性。方法纳入2021年1月—2022年12月的40例子痫前期高血压患者,参照随机数字表法划分对照组(纳入20例,行硫酸镁+硝苯地平治疗)、观察组(纳入20例,加用拉贝洛尔),评价组间血压、心率(HR)、子宫动脉血流指标、凝血指标、生化指标、氧化应激产物、用药不良反应(ADR)。结果(1)治疗后,观察组血压[舒张压(DBP)、收缩压(SBP)]、HR、子宫动脉血流指标[子宫动脉血流阻力指数(RI)、收缩期最大血流速度/舒张末期血流速率(S/D)、搏动指数(PI)]、凝血指标[纤维蛋白原(FIB)]、生化指标[24h尿蛋白定量(24h UP)、同型半胱氨酸(Hcy)、C反应蛋白(CRP)]、氧化应激产物[丙二醇(MDA)]更低,凝血指标[活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)]更长,氧化应激产物[超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)]更高,P<0.05;(2)在ADR方面,观察组(20.00%)与对照组(15.00%)无差异,P>0.05。结论对子痫前期高血压患者行硫酸镁+硝苯地平+拉贝洛尔治疗,能够降压、降低HR,改善子宫动脉血流、凝血功能、生化指标、氧化应激失衡,加之ADR少,值得推广。

Objective To evaluate the value and effectiveness of magnesium sulfate combined with nifedipine and labelolol in patients with preeclampsia and hypertension.Method Forty patients with preeclamptic hypertension from January 2021 to December 2022 were included,and were divided into control group(20 cases included,receiving magnesium sulfate+nifedipine treatment)and observation group(20 cases included,plus labeolol)according to random number table method.Blood pressure,heart rate(HR),uterine artery blood flow index,coagulation index,biochemical index,oxidative stress products and adverse drug reaction(ADR)were evaluated between groups.Results(1)After treatment,In observation group,blood pressure[diastolic blood pressure(DBP),systolic blood pressure(SBP)],HR,uterine artery blood flow index[uterine artery blood flow resistance index(RI),systolic maximum blood flow velocity/end-diastolic blood flow rate(S/D),pulsation index(PI)],coagulation index[fibrinogen(FIB)],biochemical index[24h urinary protein quantity(24h)]UP),homocysteine(Hcy),C-reactive protein(CRP)],oxidative stress products[propylene glycol(MDA)]were lower,and coagulation indexes[activated partial thromboplastin time(APTT),prothrombin time(PT)]were longer.The oxidative stress products[superoxide dismutase(SOD),glutathione peroxidase(GSH-Px)]were higher,P<0.05;(2)There was no difference in ADR between the observation group(20.00%)and the control group(15.00%),P>0.05.Conclusion Magnesium sulfate+nifedipine+labelolol can reduce blood pressure,HR,improve uterine artery blood flow,coagulation function,biochemical indexes,oxidative stress imbalance,and less ADR in the treatment of hypertension patients with preeclampsia,worthy of promotion.